IN Research: NanoMark Therapeutics - website - "AUra"

also: Product Pipeline (2011)  

(in research) as per the website:
"To alleviate the fear and provide relief to those brave patients battling with ovarian cancer, Nanomark Therapeutics (NMT) has developed the revolutionary and first product of its kind, AUra. The drug formulation is the only targeted ovarian cancer therapy in the world and works by selectively binding to receptors found exclusively on cancer cells, using the receptor as a docking station and the nanoparticles as vehicles of entry into the cell for the cancer medication.
This exclusive binding exhibits targeted therapy, eliminating only cancer cells, while sparing the healthy, normal cells. This, in turn, eradicates many side effects including hair loss, fatigue and nausea. President and CSO, Dr. Sham Kakar, is the primary inventor of AUra and the first scientist ever to clone the specific receptor from breast and ovarian cancers. While targeting cancer cells, AUra not only spares healthy cells, but also reduces medicine dosage 200 fold, further minimizing and potentially completely eliminating side effects. US and International Patent filed by the Office of Technology Transfer (OTT) at the University of Louisville (U of L) on 6/18/2009 covers the technology that can be applicable to 12 different cancer types. NMT holds the exclusive licensing option to this patent. The promise and value of AUra has been widely recognized via funded research grants in excess of $233,000 since 2006, with an additional $1.85M in grants expected in 2010. NMT is pleased to share that AUra has successfully passed Round 1 animal testing and is currently in Round 2 to test cytotoxicity, pharmacokinetics and efficacy of AUra. First-round animal study results have shown that AUra suppresses tumor growth and decreases dosage requirement of the cancer medication, Doxorubicin, 200-fold. Side effects from AUra, if any, are expected to be minimal."